WO1995018622A1 - Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents - Google Patents

Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents Download PDF

Info

Publication number
WO1995018622A1
WO1995018622A1 PCT/US1995/000055 US9500055W WO9518622A1 WO 1995018622 A1 WO1995018622 A1 WO 1995018622A1 US 9500055 W US9500055 W US 9500055W WO 9518622 A1 WO9518622 A1 WO 9518622A1
Authority
WO
WIPO (PCT)
Prior art keywords
colon cancer
hydroxy
phenylazobenzoic acid
acid derivatives
chemotherapeutic agents
Prior art date
Application number
PCT/US1995/000055
Other languages
French (fr)
Inventor
Lorin K. Johnson
Marvin H. Sleisenger
Original Assignee
Salix Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP95907293A priority Critical patent/EP0738152B1/en
Priority to CA002180571A priority patent/CA2180571C/en
Priority to DE69534564T priority patent/DE69534564T2/en
Priority to RO96-01403A priority patent/RO116525B1/en
Priority to US08/669,377 priority patent/US5905073A/en
Priority to NZ279062A priority patent/NZ279062A/en
Application filed by Salix Pharmaceuticals, Inc. filed Critical Salix Pharmaceuticals, Inc.
Priority to AT95907293T priority patent/ATE308327T1/en
Priority to AU15575/95A priority patent/AU691869B2/en
Priority to JP7518558A priority patent/JPH09510958A/en
Publication of WO1995018622A1 publication Critical patent/WO1995018622A1/en
Priority to FI962735A priority patent/FI962735A/en
Priority to NO962841A priority patent/NO962841L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides a method of colon cancer chemoprevention or chemotherapy comprising administering to an individual suffering from colon cancer or at risk to develop colon cancer a pharmaceutical composition comprising an effective amount of a 2-hydroxy-5-phenylazobenzoic acid derivative or an ester of an active metabolite or an oxidation product of an active metabolite thereof, or a pharmacologically acceptable salt of the 2-hydroxy-5-phenylazobenzoic acid derivative or an ester or an active metabolite or an oxidation product of an active matabolite thereof.
PCT/US1995/000055 1994-01-07 1995-01-06 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents WO1995018622A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002180571A CA2180571C (en) 1994-01-07 1995-01-06 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
DE69534564T DE69534564T2 (en) 1994-01-07 1995-01-06 USE OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES AS ACTIVE AGENTS FOR THE CHEMOPLE PREVENTION AND CHEMOTHERAPY OF COLONY CANCER
RO96-01403A RO116525B1 (en) 1994-01-07 1995-01-06 Method for treatment and prevention of colon cancer
US08/669,377 US5905073A (en) 1995-01-06 1995-01-06 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
NZ279062A NZ279062A (en) 1994-01-07 1995-01-06 Use of phenylazosalicylic acid derivatives for treatment/prevention of colon cancer
EP95907293A EP0738152B1 (en) 1994-01-07 1995-01-06 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
AT95907293T ATE308327T1 (en) 1994-01-07 1995-01-06 USE OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES AS ACTIVE INGREDIENTS FOR CHEMOPREVENTION AND CHEMOTHERAPY OF COLON CANCER
AU15575/95A AU691869B2 (en) 1994-01-07 1995-01-06 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
JP7518558A JPH09510958A (en) 1994-01-07 1995-01-06 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as chemopreventive and chemo therapeutic agents for colorectal cancer
FI962735A FI962735A (en) 1994-01-07 1996-07-03 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as a preventive for colon cancer and chemotherapeutic agent
NO962841A NO962841L (en) 1994-01-07 1996-07-05 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives such as colon cancer chemopreventives and chemotherapeutic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/178,578 US5498608A (en) 1994-01-07 1994-01-07 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US08/178,578 1994-01-27

Publications (1)

Publication Number Publication Date
WO1995018622A1 true WO1995018622A1 (en) 1995-07-13

Family

ID=22653104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/000055 WO1995018622A1 (en) 1994-01-07 1995-01-06 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents

Country Status (18)

Country Link
US (1) US5498608A (en)
EP (1) EP0738152B1 (en)
JP (4) JPH09510958A (en)
CN (1) CN1140994A (en)
AT (1) ATE308327T1 (en)
AU (1) AU691869B2 (en)
CA (1) CA2180571C (en)
CZ (1) CZ286460B6 (en)
DE (1) DE69534564T2 (en)
DK (1) DK0738152T3 (en)
ES (1) ES2248796T3 (en)
FI (1) FI962735A (en)
HU (1) HUT74512A (en)
NO (1) NO962841L (en)
NZ (1) NZ279062A (en)
RO (1) RO116525B1 (en)
RU (1) RU2161487C2 (en)
WO (1) WO1995018622A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760638A1 (en) * 1997-03-14 1998-09-18 Astra Ab FORMULATION OF BALSALAZIDE
US6277412B1 (en) 1997-07-30 2001-08-21 Dr. Falk Pharma Gmbh Pellet-type formulation intended for treating the intestinal tract
US6677319B1 (en) 1998-08-06 2004-01-13 Wolfgang Stremmel Phosphatidylcholine as medication with protective effect large intestinal mucosa
US7625884B2 (en) 2005-08-24 2009-12-01 Salix Pharmaceuticals, Ltd Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US7838527B2 (en) 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
US7875624B2 (en) 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
WO2011024122A1 (en) 2009-08-26 2011-03-03 Nordic Pharma Pharmaceutical compositions for treating ibd
WO2011137103A1 (en) 2010-04-26 2011-11-03 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
US8299081B2 (en) 2005-05-13 2012-10-30 Novartis Ag Methods for treating drug resistant cancer
EP2529729A1 (en) 2005-08-24 2012-12-05 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US9937190B2 (en) 2004-02-06 2018-04-10 Salix Pharmaceuticals, Ltd Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US7026318B2 (en) * 2000-06-29 2006-04-11 Shionogi & Co., Ltd. Compounds exhibiting X-type sPLA2 inhibiting effect
EP1642885B1 (en) 2000-08-29 2009-11-11 Biocon Limited Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract
TWI314457B (en) * 2001-03-19 2009-09-11 Shionogi & Co
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
FR2867981B1 (en) 2004-03-24 2008-10-31 Genevrier Sa Lab USE OF MONO-AND DISULFATE CHONDROITINE IN THERAPEUTICS
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
CN1988897B (en) * 2004-05-28 2011-06-29 萨利克斯药物有限公司 Use of balsalazide in preparing medicine for radiation induced enteritis
US7932366B2 (en) * 2004-07-07 2011-04-26 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
RU2354384C1 (en) * 2007-12-28 2009-05-10 Михаил Владимирович Кутушов Application of organic dyes as means for treatment of oncological diseases
WO2010030781A2 (en) * 2008-09-10 2010-03-18 Numed International, Inc. Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2080796B (en) * 1980-07-21 1983-10-12 Biorex Laboratories Ltd 2-hydroxy-5-phenylazobenzoic acid derivatives
NZ212419A (en) * 1984-06-25 1988-08-30 Mucan Diagnostics Pty Ltd In vitro diagnostic test for detecting cancer cells producing mucin antigens
US5162202A (en) * 1989-12-12 1992-11-10 Shamsuddin Abulkalam M Rectal mucus test and kit for detecting cancerous and precancerous conditions
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Stedsman's Medical Dictionary", 24th. Ed., Published 1983, by WILLIAMS & WILKINS (BALTIMORE, MD), page 297. *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760638A1 (en) * 1997-03-14 1998-09-18 Astra Ab FORMULATION OF BALSALAZIDE
GR980100096A (en) * 1997-03-14 1998-11-30 Astra Aktiebolag New formulation of balsalazide
NL1008575C2 (en) * 1997-03-14 1999-09-10 Astra Ab New wording.
BE1011837A5 (en) * 1997-03-14 2000-02-01 Astra Ab NEW COMPOSITION Balsalazide.
US6197341B1 (en) 1997-03-14 2001-03-06 Stefan Friess Formulations of balsalazide and its derivatives
US6551620B2 (en) 1997-07-30 2003-04-22 Dr. Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
US8337886B2 (en) 1997-07-30 2012-12-25 Dr. Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
US6277412B1 (en) 1997-07-30 2001-08-21 Dr. Falk Pharma Gmbh Pellet-type formulation intended for treating the intestinal tract
US7547451B2 (en) 1997-07-30 2009-06-16 Dr. Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
US8956647B2 (en) 1997-07-30 2015-02-17 Dr. Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
US8940328B2 (en) 1997-07-30 2015-01-27 Dr. Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
US8911778B2 (en) 1997-07-30 2014-12-16 Dr. Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
US8496965B2 (en) 1997-07-30 2013-07-30 Dr. Falk Pharma Gmbh Pellet formulation for the treatment of the intenstinal tract
US6677319B1 (en) 1998-08-06 2004-01-13 Wolfgang Stremmel Phosphatidylcholine as medication with protective effect large intestinal mucosa
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US7838527B2 (en) 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
US10328088B2 (en) 2004-02-06 2019-06-25 Salix Pharmaceuticals, Inc. Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
US9937190B2 (en) 2004-02-06 2018-04-10 Salix Pharmaceuticals, Ltd Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
US7875624B2 (en) 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
US8299081B2 (en) 2005-05-13 2012-10-30 Novartis Ag Methods for treating drug resistant cancer
EP2586427A2 (en) 2005-08-24 2013-05-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
EP2529729A1 (en) 2005-08-24 2012-12-05 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US7625884B2 (en) 2005-08-24 2009-12-01 Salix Pharmaceuticals, Ltd Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US9192616B2 (en) 2005-08-24 2015-11-24 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
WO2011024122A1 (en) 2009-08-26 2011-03-03 Nordic Pharma Pharmaceutical compositions for treating ibd
WO2011137103A1 (en) 2010-04-26 2011-11-03 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males

Also Published As

Publication number Publication date
EP0738152B1 (en) 2005-11-02
FI962735A (en) 1996-08-26
ATE308327T1 (en) 2005-11-15
NZ279062A (en) 1999-11-29
CA2180571C (en) 2001-03-20
AU1557595A (en) 1995-08-01
HUT74512A (en) 1997-01-28
NO962841D0 (en) 1996-07-05
NO962841L (en) 1996-08-29
EP0738152A4 (en) 2000-12-13
HU9601846D0 (en) 1996-09-30
CZ196796A3 (en) 1996-12-11
JP2006096738A (en) 2006-04-13
AU691869B2 (en) 1998-05-28
US5498608A (en) 1996-03-12
DE69534564D1 (en) 2005-12-08
JP2010235629A (en) 2010-10-21
DK0738152T3 (en) 2006-01-30
JP2005320326A (en) 2005-11-17
DE69534564T2 (en) 2006-07-27
FI962735A0 (en) 1996-07-03
EP0738152A1 (en) 1996-10-23
RU2161487C2 (en) 2001-01-10
CA2180571A1 (en) 1995-07-13
JP4601466B2 (en) 2010-12-22
CN1140994A (en) 1997-01-22
JPH09510958A (en) 1997-11-04
CZ286460B6 (en) 2000-04-12
ES2248796T3 (en) 2006-03-16
RO116525B1 (en) 2001-03-30

Similar Documents

Publication Publication Date Title
WO1995018622A1 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
WO1994027587A3 (en) Sustained antiepileptic therapy
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
AU6171796A (en) Prodrugs of pharmaceuticals with improved bioavailability
CA2304704A1 (en) Formulations and methods for reducing toxicity of antineoplastic agents
CA2294913A1 (en) Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative
CA2219115A1 (en) N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs
CA2356380A1 (en) Immunosuppressive effects of pteridine derivatives
CA2192899A1 (en) Composition containing l-carnitine and hydroxycitric acid
GEP20033027B (en) Use of Substituted Benzopyran Analogs for Treatment of Inflammation
ATE424810T1 (en) A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER
HUP9601566A3 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
CA2107669A1 (en) Preparation for treating wounds and hemorrhoides
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
AU2740797A (en) Androstene derivatives
EP1666041A3 (en) Xanthine derivatives for treating neurodegenerative disorders
WO1998009599A3 (en) The new use of dicaffeoylquinic acid for treating hepatitis b and the diseases related with retrovirus, and the new caffeoylquinic acid derivatives
RU95113437A (en) Trans-2-dimethylamino-1-phenyl-3-cyclohexene-trans-1- carboxylic acid ±-ethyl ester as primary orthophosphate and solid pharmaceutical composition having pain-killing activity
WO1993017691A3 (en) Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson&#39;s disease
WO1999005103A3 (en) 2o(s)-7-ethyl-9-(n-methyl-n-phenyl)amidino-camptothecin, its preparation and its use as antitumor agent
CA2429793A1 (en) Interferon therapeutic effect enhancer
IL108246A (en) (all-e)-3,7-dimethyl-9-(3, 5-dimethyl- 2-nonyloxyphenyl)-2, 4, 6, 8-nonatetraenoic acid derivatives, their preparation and pharmaceutical compositions containing them
WO2002006299A3 (en) Therapeutic uses for aminosterol compounds
CA2409845A1 (en) Active substance combination containing a compound with an opioid effect and at least one further compound of formula i

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95191519.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PV1996-1967

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 962735

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 2180571

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/1996/002640

Country of ref document: MX

Ref document number: 279062

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 96-01403

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 08669377

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1995907293

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995907293

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1996-1967

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1996-1967

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1995907293

Country of ref document: EP